By Colin Kellaher
Stoke Therapeutics' chief executive, Edward Kaye, is stepping down after more than seven years at the helm of the biotechnology company.
Stoke on Tuesday said Ian Smith, a board member since September 2023, will step in as interim CEO, adding that it has launched a search for a permanent replacement for Kaye.
The Bedford, Mass., company said its chairman, Arthur Tzianabos, will serve as interim executive chairman and lead the CEO search.
Stoke said Kaye, who joined the company as CEO and a director in October 2017, will continue to serve as an adviser and non-executive board member.
The company said Kaye, 75 years old, will be entitled to receive payment of his current annual salary of $680,214 for 12 months, and that his existing equity awards will continue to vest as long as he is providing services as a board member or as an adviser.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 18, 2025 07:22 ET (11:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。